Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds
International Journal of Molecular Sciences · 22.12.2025 · 27 (1) · 101
DOI: 10.3390/ijms27010101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.12.2025. Verfasst von Carlos García-Estrada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain. Hauptthemen laut MEDLINE: Fungi, Antineoplastic Agents, Secondary Metabolism, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 309 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer remains one of the leading causes of death worldwide, and resistance to conventional therapies underscores the need for the discovery of novel antitumor agents. The ongoing search for novel natural sources offers promising avenues for discovering unique anticancer compounds with new mechanisms of action. One of these natural sources is represented by fungi, a prolific group of endophytic and non-endophytic eukaryotes able to produce bioactive secondary metabolites, many of which exhibit potent antitumor properties. These natural compounds display diverse chemical structures including polyketides, terpenoids, alkaloids, amino acid-derived compounds, phenols, etc. Their mechanisms of action are equally varied, ranging from induction of apoptosis and cell cycle arrest to inhibition of angiogenesis and metastasis. In this review we describe some potential antitumor compounds of fungal origin, together with the characteristics and biosynthesis of three representative types of antitumor compounds produced by filamentous fungi: squalene-derived sterol-type antitumor agents, prenylated diketopiperazine antitumor metabolites and meroterpenoid antitumor compounds. The ongoing scientific debate regarding the presence of paclitaxel biosynthetic genes in fungi is also discussed. As drug resistance remains a challenge in cancer therapy, fungal compounds offer a valuable reservoir for the development of new chemotherapeutic agents with novel modes of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Ciencias Biomédicas, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
- Instituto de Biomedicina (IBIOMED), Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
- IBIOLEÓN (Instituto de Investigación Biosanitaria de León), Hospital de León, Altos de Nava s/n, 24071 León, Spain.
- Área de Bioquímica y Biología Molecular, Departamento de Biología Molecular, Facultad de Veterinaria, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
- Instituto de Biología Molecular, Genómica y Proteómica (INBIOMIC), Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
- Área de Microbiología, Departamento de Biología Molecular, Facultad de Ciencias Biológicas y Ambientales, Universidad de León, Campus de Vegazana s/n, 24007 León, Spain.
ORCID-Profile: Carlos García-Estrada, Carlos Barreiro
Zitieren
APA
García-Estrada, C., Barreiro, C., & Martín, J. F. (2025). Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds. International Journal of Molecular Sciences, 27(1), 101. https://doi.org/10.3390/ijms27010101
Vancouver
García-Estrada C, Barreiro C, Martín JF. Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds. International Journal of Molecular Sciences. 2025;27(1):101. doi:10.3390/ijms27010101
BibTeX
@article{GarcaEstrada2025,
author = {García-Estrada, Carlos and Barreiro, Carlos and Martín, Juan F},
title = {Anticancer Secondary Metabolites Produced by Fungi: Potential and Representative Compounds},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {27},
number = {1},
pages = {101},
doi = {10.3390/ijms27010101}
}
EUVIMED